Advertisement
Novara — A Smarter Way to Access Global Markets
LIVE DESK·Global markets desk

Earnings

Cencora says GLP-1 revenue surges 25%, calls fiscal 2026 'excellent' at Wells Fargo conference
EarningsArticle

Cencora says GLP-1 revenue surges 25%, calls fiscal 2026 'excellent' at Wells Fargo conference

Pharmaceutical distributor Cencora reported Q3 GLP-1 revenue of $2.3 billion, up 25% year over year, and disclosed a $1 billion share repurchase as management highlighted specialty growth across its portfolio.

Priya Anand · 14 Sept 2026
Coupang Stock Hits 52-Week Low as Earnings Miss and Margin Pressure Mounts
EarningsArticle

Coupang Stock Hits 52-Week Low as Earnings Miss and Margin Pressure Mounts

South Korean e-commerce giant Coupang shares fell to $14.92, down 53.5% over the past year, after Q2 revenue missed and EBITDA margins contracted 320 basis points.

Priya Anand · 14 Sept 2026
ABM Industries Reports Record Q3 Revenue of $2.3 Billion, Raises Full-Year Guidance
EarningsArticle

ABM Industries Reports Record Q3 Revenue of $2.3 Billion, Raises Full-Year Guidance

The facilities services company posted record quarterly revenue of $2.3 billion and lifted adjusted EPS and free-cash-flow forecasts, driven by strong demand in semiconductors, microgrids and data centers.

Priya Anand · 14 Sept 2026
UNFI Q4 Earnings: EBITDA Surges 48%, Leverage Hits Lowest Since 2018
EarningsArticle

UNFI Q4 Earnings: EBITDA Surges 48%, Leverage Hits Lowest Since 2018

United Natural Foods reported a 48% jump in fourth-quarter adjusted EBITDA to $172 million and swung to earnings per share of $0.69, while net debt fell to its lowest level in eight years.

Priya Anand · 14 Sept 2026
Marathon Petroleum stock hits all-time high at $398.68 after Q2 beat
EarningsArticle

Marathon Petroleum stock hits all-time high at $398.68 after Q2 beat

Marathon Petroleum shares reached a record $398.68 after second-quarter 2026 EPS of $17.73 and revenue of $52.34 billion exceeded analyst estimates.

Priya Anand · 14 Sept 2026
Kyndryl reaffirms flat FY27 revenue, projects low‑single‑digit FY28 growth as AI gains traction
EarningsArticle

Kyndryl reaffirms flat FY27 revenue, projects low‑single‑digit FY28 growth as AI gains traction

The IT services firm said Q1 FY27 revenue fell 3% YoY, kept FY27 revenue guidance at flat to -2%, and expects modest growth in FY28, citing expanding hyperscaler business and AI‑driven efficiency.

Priya Anand · 14 Sept 2026
UNFI beats Q4 fiscal 2026 EPS, stock rises 1.7%
EarningsArticle

UNFI beats Q4 fiscal 2026 EPS, stock rises 1.7%

United Natural Foods reported adjusted EPS of $0.69 and record annual free cash flow, while guiding fiscal 2027 sales to $31.2 billion to $31.8 billion.

Priya Anand · 14 Sept 2026
L'Oréal Reports 6.5% Organic Sales Growth, Outpaces Market at Barclays Conference
EarningsArticle

L'Oréal Reports 6.5% Organic Sales Growth, Outpaces Market at Barclays Conference

The cosmetics giant posted first-half organic growth of 6.5%, running about 200 basis points ahead of a ~4.5% market, while raising its longer-term SG&A efficiency target to 15% of sales.

Priya Anand · 14 Sept 2026
Canaan Q2 revenue misses guidance; self-mining reaches 55% of sales
EarningsArticle

Canaan Q2 revenue misses guidance; self-mining reaches 55% of sales

Canaan reported Q2 2026 revenue of $31.9 million, below its $35 million to $45 million guidance, as self-mining reached 55% of sales; shares fell on a weak Q3 outlook.

Priya Anand · 14 Sept 2026
SECO Raises 2027 Revenue Outlook on Record Q3 Guidance and Robotics Push
EarningsArticle

SECO Raises 2027 Revenue Outlook on Record Q3 Guidance and Robotics Push

Italian embedded computing maker SECO guides Q3 revenue to ~€60M, its highest quarter ever, as a Neura Robotics partnership and strong order backlog drive shares up over 10%.

Priya Anand · 14 Sept 2026
Seco lifts 2027 outlook to at least EUR 270 million after Q2 2026 results
EarningsArticle

Seco lifts 2027 outlook to at least EUR 270 million after Q2 2026 results

Seco shares rose 9.7% to $3.86 after Q2 2026 gross margin reached 56%, Q3 revenue guidance was set near EUR 60 million, and 2027 base-case revenue was raised to at least EUR 270 million.

Priya Anand · 14 Sept 2026
Alnylam's TTR Franchise Tops $1B Quarterly Revenue 18 Months After Launch
EarningsArticle

Alnylam's TTR Franchise Tops $1B Quarterly Revenue 18 Months After Launch

Alnylam Pharmaceuticals reported its TTR franchise surpassed $1 billion in quarterly revenue roughly 18 months after its cardiomyopathy launch, as overall revenue jumped 95% year over year to $4.8 billion.

Priya Anand · 14 Sept 2026
Universal Health Services Lowers Full-Year Guidance as Exchange Headwinds Mount
EarningsArticle

Universal Health Services Lowers Full-Year Guidance as Exchange Headwinds Mount

UHS trimmed its full-year adjusted admissions outlook and EBITDA midpoint after a 2.9% Q2 gain, citing exchange-market shifts and higher malpractice costs amid its Talkspace deal.

Priya Anand · 14 Sept 2026
Liquidia targets $1 bn run‑rate as it expands inhaled prostacyclin pipeline
EarningsArticle

Liquidia targets $1 bn run‑rate as it expands inhaled prostacyclin pipeline

At the Wells Fargo Healthcare Conference, Liquidia outlined a $1 bn annual run‑rate goal, $170 m Q2 2026 YUTREPIA revenue and a growing pipeline that includes the L606 inhaled treprostinil program.

Priya Anand · 14 Sept 2026
ABM posts record Q3 2026 revenue of $2.3B, raises EPS outlook
EarningsArticle

ABM posts record Q3 2026 revenue of $2.3B, raises EPS outlook

ABM Industries reported record Q3 2026 revenue of $2.3 billion and raised full-year adjusted EPS guidance to $3.95-$4.10, while shares slipped in premarket trading.

Priya Anand · 14 Sept 2026
Argan Reports Record Q2 Revenue on Power Project Demand
EarningsArticle

Argan Reports Record Q2 Revenue on Power Project Demand

Infrastructure contractor Argan posted record $384 million in second-quarter revenue, driven by its power segment and electrification projects, as the company sees a $2.5 billion backlog supporting future growth.

Priya Anand · 14 Sept 2026
Revenio Reports Q2 Profit Drop as Visionix Acquisition Weighs on Margins
EarningsArticle

Revenio Reports Q2 Profit Drop as Visionix Acquisition Weighs on Margins

Revenue jumped 48% year-on-year but operating profit fell 61% as Visionix acquisition costs and lower-margin sales compressed margins, while net gearing surged to roughly 160%.

Priya Anand · 14 Sept 2026
Revenio shares plunge 18% as Q2 margin squeeze weighs on Visionix integration
EarningsArticle

Revenio shares plunge 18% as Q2 margin squeeze weighs on Visionix integration

Revenio Group shares fell more than 18% after Q2 gross margin collapsed nearly 8 percentage points to 64.7%, as integration costs and a delayed AI product pushed profitability below expectations.

Priya Anand · 13 Sept 2026
Theon International posts 35% revenue rise in H1 2026, lifts EBIT margin outlook
EarningsArticle

Theon International posts 35% revenue rise in H1 2026, lifts EBIT margin outlook

The defense optics maker reported EUR 248.7 million revenue, 38% jump in order intake and raised full‑year EBIT margin target to at least 26%.

Priya Anand · 13 Sept 2026
Canaan Q2 2026 revenue misses guidance, shares fall premarket
EarningsArticle

Canaan Q2 2026 revenue misses guidance, shares fall premarket

Canaan reported Q2 2026 revenue of about $32 million, below its $35 million to $45 million guidance, and guided Q3 revenue to $11 million to $15 million as shares fell in premarket trade.

Priya Anand · 13 Sept 2026
McKesson Reports Strong Q1 Performance at Wells Fargo Healthcare Conference
EarningsArticle

McKesson Reports Strong Q1 Performance at Wells Fargo Healthcare Conference

McKesson Corporation reported robust Q1 financial results and outlined its growth strategy, including a $2.25 billion acquisition and a focus on oncology and biopharma services.

Priya Anand · 13 Sept 2026
Novartis Cardiovascular Trial Fails to Meet Primary Endpoint
EarningsArticle

Novartis Cardiovascular Trial Fails to Meet Primary Endpoint

Pelacarsen lowered Lp(a) levels but failed to reduce cardiovascular events in 8,323-patient Phase III trial, dealing a blow to Novartis's heart disease pipeline.

Priya Anand · 13 Sept 2026
Old Mutual lifts returns but profit slips on storm losses
EarningsArticle

Old Mutual lifts returns but profit slips on storm losses

Old Mutual reported higher mid-term return metrics and strong investment-segment growth in H1 2026, but adjusted headline earnings per share fell 27% as insurance losses from May storms weighed on results.

Priya Anand · 13 Sept 2026
Funding Circle profit quadruples in H1 despite 8.7% share decline
EarningsArticle

Funding Circle profit quadruples in H1 despite 8.7% share decline

Lending marketplace reports £24.1m profit before tax, up fourfold year-over-year, while upgrading full-year revenue and profit guidance.

Priya Anand · 13 Sept 2026